Belpointe Asset Management LLC Vertex Pharmaceuticals Inc Transaction History

Belpointe Asset Management LLC

$1.49 Billion
Q3 2024

A detailed history of Belpointe Asset Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Belpointe Asset Management LLC holds 1,247 shares of VRTX stock, worth $582,436. This represents 0.04% of its overall portfolio holdings.

Number of Shares

1,247

Previous 1,102 13.16%

Holding current value

$582,436

Previous $516,000 12.21%

% of portfolio

0.04%

Previous 0.04%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$460.0 - $505.78 $66,700 - $73,338	145 Added 13.16%	1,247 $579,000
Q2 2024 Aug 02, 2024	BUY	$392.81 - $485.53 $29,853 - $36,900	76 Added 7.41%	1,102 $516,000
Q1 2024 May 08, 2024	BUY	$407.69 - $446.08 $121,083 - $132,485	297 Added 40.74%	1,026 $428,000
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $17,150 - $20,534	50 Added 7.36%	729 $296,000
Q3 2023 Nov 15, 2023	SELL	$338.18 - $362.46 $81,163 - $86,990	-240 Reduced 26.12%	679 $236,000
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $187,079 - $209,386	-595 Reduced 39.3%	919 $323,000
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $949,103 - $1.08 Million	-3,351 Reduced 68.88%	1,514 $477,000
Q4 2022 Feb 08, 2023	SELL	$285.76 - $321.48 $589,237 - $662,891	-2,062 Reduced 29.77%	4,865 $1.4 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $436,211 - $486,709	1,593 Added 29.87%	6,927 $2.01 Million
Q2 2022 Aug 02, 2022	SELL	$234.96 - $292.55 $78,476 - $97,711	-334 Reduced 5.89%	5,334 $1.5 Million
Q1 2022 Apr 28, 2022	SELL	$221.42 - $260.97 $68,640 - $80,900	-310 Reduced 5.19%	5,668 $1.48 Million
Q4 2021 Feb 15, 2022	BUY	$177.01 - $223.45 $49,739 - $62,789	281 Added 4.93%	5,978 $1.29 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $46,798 - $52,371	258 Added 4.74%	5,697 $1.03 Million
Q2 2021 Aug 09, 2021	BUY	$187.49 - $221.1 $168,178 - $198,326	897 Added 19.75%	5,439 $1.1 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $714,011 - $832,278	3,449 Added 315.55%	4,542 $976,000
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $73,281 - $97,735	354 Added 47.9%	1,093 $258,000
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $75,672 - $89,717	-296 Reduced 14.81%	1,702 $405,000
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $246,190 - $291,885	-963 Reduced 56.58%	739 $201,000
Q2 2020 Jul 20, 2020	BUY	$225.48 - $295.8 $66,742 - $87,556	296 Added 17.39%	1,998 $580,000
Q1 2020 Jul 20, 2020	SELL	$199.77 - $247.81 $232,532 - $288,450	-1,164 Reduced 40.61%	1,702 $405,000
Q4 2019 Feb 18, 2020	BUY	$166.71 - $223.91 $477,790 - $641,726	2,866 New	2,866 $628,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belpointe Asset Management LLC with notifications on news.

Account

Belpointe Asset Management LLC Vertex Pharmaceuticals Inc Transaction History